Excedr Monthly | September, 2024

Hey everyone, we're back with the latest edition of Excedr Monthly, a biotech newsletter for founders, scientists, and the broader life sciences community—full of resources to help you navigate the ins and outs of a tough industry. Let's jump in.

In today's newsletter:

• The latest from The Biotech Startups Podcast ???
• Quick biotech news roundup ??
• Editor's picks from the blog ??

Latest from the Biotech Startups Podcast—

Presented by Excedr, a podcast for scientist-entrepreneurs.

This month's guests included:

• Doug Drysdale, the CEO at Cybin, a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics, whose goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
• Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry. In addition to his Board work, Derek previously held leadership positions at DSM, and was the Founder and CEO of Xcelience, which he eventually sold to Capsugel Lonza in 2016.?
• Barbara Alcaraz Silva, Executive Director of Early Stage Life Sciences and Healthcare, Startup Banking at J.P. Morgan. Barbara is a former researcher and founder, whose graduate studies focused on Telomeres and DNA Repair. Prior to J.P. Morgan, Barbara has worked many startups, both as an advisor and an investor.

Find all the latest episodes of The Biotech Startups Podcast here.

Quick Biotech News Roundup—

• DCVC Bio founders look for more quick returns, less overhyped AI
• Novo obesity prospect linked to 'mild to moderate neuropsychiatric side effects'
• For some multiple myeloma patients, Carvykti cut risk of death by 45%
• Foundation models build on ChatGPT tech to learn the fundamental language of biology
• Pfizer to pull sickle cell drug from market, shut down trials
• Roche doubles down on breast cancer with $850M for Regor's CDK inhibitors
• Why drug distributors are buying cancer specialists
• Top 50 NIH-Funded Institutions of 2024

Blog Posts—

Editor's Picks from the Excedr Blog.

The Benefits of Non-Dilutive Capital for Life Science Startups

Securing the right type of funding is a huge part of any life sciences or biotech startup. Such a small percentage can or successfully do bootstrap, due to the high costs required to support research and development, and bring products to market. Non-dilutive capital stands out as a valuable resource for early-stage companies.

How to Improve Venture Funding Outcomes with Equipment Leasing

For startups seeking venture capital, securing the right financial strategies is crucial to attracting investors and ensuring long-term success. One of the most effective strategies for enhancing a startup’s financial health and appeal to venture capitalists is equipment leasing. Leasing allows startups to access the necessary equipment without the burden of large upfront costs, which can significantly improve cash flow and profitability.?

How to Break into Biotech BD as a PhD student

Transitioning from academia to a business development (BD) role in the life sciences is both challenging and rewarding. For many PhD students, the prospect of moving away from the lab bench into the world of business may seem daunting. However, BD roles offer a unique opportunity to leverage your scientific expertise while driving the commercial success of groundbreaking innovations.?

Maximizing Equipment ROI: Invest in the Right Lab Instruments

Lab operations have become more complex and technology-driven, making it even more important to identify ways in which to optimize ROI, whether you're a lab manager, CSO, founder—any decision maker involved in the decisions behind equipment procurement and equipment financing.?

Key Steps to Creating a Business Partnership Proposal?

Your business or startup is at a point where you and your team are looking to strike up meaningful partnerships with like-minded companies in your industry. Creating a compelling partnership proposal is a critical step in forging successful collaborations that can drive your business’s growth and fuel future innovation.

Till next time.

-Tom & the team at Excedr ??????